NCT04241341
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 3
Drug Category: Other
Key Eligibility Criteria:
Gender: Female
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions:
https://ClinicalTrials.gov/show/NCT04241341